Boardroom Alpha
Meeting calendar
COR · Annual meeting · Thursday, March 5, 2026

Cencora Inc

11 nominees · 4 ballot items.

Election of 11 directors; advisory (non-binding) approval of fiscal 2025 executive compensation (say-on-pay); ratification of Ernst & Young LLP as independent auditors for fiscal 2026; and transaction of any other properly brought business at the meeting.

Market cap
$59.9B
1Y TSR
-0.2%
Board grade
B-
Record date
Jan 12, 2026
Filing
DEF 14A
Meeting concluded · Mar 5, 2026

Follow how the vote landed and what changed on Cencora Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot4

  1. 1

    Elect the 11 directors named in the proxy statement

    ManagementBoard: FOR

    Elect 11 nominees to the Board of Directors to serve a one-year term until the 2027 annual meeting.

  2. 2

    Advisory vote to approve the fiscal 2025 compensation of Cencora’s named executive officers

    ManagementBoard: FOR

    Non-binding, advisory approval (say-on-pay) of the fiscal 2025 compensation paid to the company's named executive officers as disclosed in the proxy statement.

    More detail

    This advisory proposal asks shareholders to approve, on a non-binding basis, the fiscal 2025 compensation paid to Cencora’s named executive officers as disclosed in the proxy statement. Management is seeking shareholder approval to signal support for its executive compensation design, which emphasizes a high proportion of at-risk and performance-based pay tied to both annual and multi-year metrics. The company’s fiscal 2025 program included a short-term annual incentive weighted to Adjusted Operating Income, Adjusted EPS, Adjusted Free Cash Flow, and a Corporate Responsibility metric, and long-term performance shares tied to Adjusted EPS CAGR and Average Annual Adjusted ROIC with a relative TSR modifier; these features are intended to align executives’ interests with shareholders and to balance short- and long-term performance. The Board recommends a vote FOR the proposal, citing strong fiscal 2025 financial results (including revenue growth, Adjusted EPS improvement, and total shareholder return) and substantial shareholder support for prior say-on-pay votes. The vote is advisory and not binding, but the Board and Compensation Committee state they will consider shareholder feedback and may adjust compensation practices if substantial adverse votes occur. The proposal’s context includes recent CEO succession and other governance changes, robust shareholder engagement, and disclosed clawback and stock ownership and holding requirements intended to mitigate excessive risk-taking. Key governance features—such as caps on payouts, post-vest holding requirements, use of non-GAAP measures reviewed quarterly, and independent consultant advice—are part of management’s rationale for recommending approval. An analyst evaluating this proposal should weigh the program’s alignment of pay with measurable performance metrics, the Board’s engagement with shareholders and past high say-on-pay support, the non-binding nature of the vote, and potential sensitivity of non-GAAP adjustments and retained discretion by the Compensation Committee in final payouts.

  3. 3

    Ratify the appointment of Ernst & Young LLP as Cencora’s independent registered public accounting firm for fiscal 2026

    ManagementBoard: FOR

    Ratify the Audit Committee’s appointment of Ernst & Young LLP as Cencora’s independent registered public accounting firm for the fiscal year ending September 30, 2026.

  4. 4

    Transact any other business properly brought before the meeting

    Management

    Consider and vote on any other matters properly presented at the annual meeting that are not already described in the proxy materials.

    More detail

    This is a catch-all, procedural proposal that grants the meeting attendees and proxy holders authority to consider and vote on any additional matters that are properly brought before the annual meeting but are not specifically described in the proxy materials. Management includes this item to ensure the proxies it solicits may be used to vote on unforeseen or ad hoc items that arise at the meeting, such as minor procedural motions, ministerial shareholder requests, or other business that satisfies the Company’s advance-notice and SEC requirements. There is no specific substantive action requested by the Board in connection with this item, and typically no recommendation is provided; accordingly, shareholders should treat any such business on a case-by-case basis. From a governance perspective, the presence of this item does not alter the substantive agenda, but it can be a vehicle for timely procedural matters or, in rare cases, for shareholder-nominated items that meet the Company’s bylaws and SEC timing requirements. Analysts should note that this item does not supplant the formal advance-notice and Rule 14a-8 processes for shareholder proposals; it merely preserves the ability to address properly presented matters at the meeting. Because outcomes under this item depend on the specific matters presented at the meeting, shareholders seeking to influence governance should rely on advance submission processes to ensure their proposals are disclosed and vetted prior to the meeting. The Board gave no specific voting recommendation for this item, reflecting its procedural nature and the unpredictability of any potential matters that could arise under it.

Director elections

Nominees on the ballot11

Independent
Tenure on this board
1.8 yrs
Also a director at
Revolution Medicines Inc (RVMD)Kailera Therapeutics Inc (KLRA)
Independent
Tenure on this board
0.5 yrs
Also a director at
Lincoln National Corp (LNC)
Independent
Tenure on this board
3.8 yrs
Also a director at
Revolution Medicines Inc (RVMD)
Independent
Tenure on this board
6.5 yrs
Also a director at
Morgan Stanley (MS)
Independent
Tenure on this board
1.1 yrs
Also a director at
Eaton Corp PLC (ETN)Norfolk Southern Corp (NSC)
Independent
Tenure on this board
2.8 yrs
Also a director at
Centene Corp (CNC)
Ownership

Top institutional holders10

Latest 13F quarter
1VANGUARD CAPITAL MANAGEMENT LLC6.3%12,313,459$3.9B
2VANGUARD PORTFOLIO MANAGEMENT LLC4.9%9,590,414$3.0B
3STATE STREET CORP4.7%9,190,551$2.9B
4BlackRock, Inc.4.4%8,624,375$2.7B
5PRICE T ROWE ASSOCIATES INC /MD/3.6%6,947,538$2.2B
6T. Rowe Price Investment Management, Inc.3.2%6,294,296$2.0B
7GEODE CAPITAL MANAGEMENT, LLC2.5%4,943,022$1.6B
8FMR LLC2.5%4,813,550$1.5B
9BlackRock, Inc.2.2%4,343,188$1.4B
10JPMORGAN CHASE CO2.0%3,986,762$1.2B
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the Cencora Inc 2026 annual meeting?
Cencora Inc (COR) holds its 2026 annual shareholder meeting on Thursday, March 5, 2026.
What is the record date for the Cencora Inc 2026 meeting?
The record date for the Cencora Inc 2026 meeting is Monday, January 12, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for Cencora Inc's 2026 meeting?
The board is presenting 11 director nominees at the Cencora Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the Cencora Inc 2026 meeting?
Shareholders will vote on 4 proposals at the Cencora Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer